Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system

Abstract

The novel non-conventional metallodrug [(η⁶-p-cymene)₂Ru₂mitoxantronato]Cl₂ (1) exhibits redox activity, DNA intercalation ability, cathepsin B and D inhibition and in vitro antitumor activity able to circumvent cisplatin resistance. Moreover, 1 can be successfully incorporated into MIL100(Fe) as a proof of concept of the feasibility of metal–organic frameworks as carriers of non-conventional drugs.